Volume XXXI, No. 2 – February 5, 2024
Table of Contents
Articles
Who’s For and Against FDA Draft LDT Rule?
FDA & CMS Issue Letter, Agree on LDT Oversight
Feds Bar Elizabeth Holmes from Government Health Programs
Published Data Show Claim Denials on the Rise, But Why?
European Lab’s Data Breach Has Lessons for U.S. Clinical Labs
Invitae Cuts Costs to Rebuild Oncology Testing Pipeline
Intelligence
Commentary & Opinion by R. Lewis Dark